Valuation: Geron Corporation

Market Cap 88Cr 77Cr 71Cr 67Cr 124.7Cr 8.29TCr 127.29Cr 853.75Cr 330.35Cr 4.1TCr 330.02Cr 322.81Cr 14TCr P/E 2026 *
-68.5x
P/E 2027 * 21.1x
Enterprise Value 86Cr 75Cr 69Cr 65Cr 121.72Cr 8.09TCr 124.25Cr 833.38Cr 322.47Cr 4TCr 322.15Cr 315.11Cr 14TCr EV / Sales 2026 *
3.67x
EV / Sales 2027 * 2.13x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-4.01%
1 week-1.87%
Current month+5.20%
1 month+2.73%
3 months-14.61%
6 months-4.01%
Current year-0.38%
1 week 1.27
Extreme 1.27
1.47
1 month 1.08
Extreme 1.08
1.47
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

2,20,000 0.0343%
20/05Free

Director

2,20,000 0.0343%
20/05Free

Director

2,20,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-4.01%-1.87%-14.05%-57.17% 88Cr
+0.33%+1.37%+64.03%+119.11% 5.53TCr
+0.82%+15.05%+74.28%+86.70% 5.19TCr
-0.59%-1.01%-15.88%-16.51% 2.28TCr
+0.89%+7.07%+3.77%+430.29% 2.26TCr
-0.18%+7.20%+28.56%-12.48% 1.74TCr
-1.10%+4.00%+28.70%-34.51% 1.61TCr
-3.35%+8.96%+135.18%+294.38% 1.4TCr
+2.13%+5.84%+26.13%+179.29% 1.34TCr
+1.31%+0.53%+27.21% - 1.23TCr
Average -0.38%+5.42%+35.79%+109.90% 2.27TCr
Weighted average by Cap. +0.18%+5.32%+46.95%+121.99%

Financials

2026 *2027 *
Net sales 23Cr 20Cr 19Cr 18Cr 33Cr 2.2TCr 34Cr 227.06Cr 88Cr 1.09TCr 88Cr 86Cr 3.78TCr 33Cr 29Cr 27Cr 25Cr 47Cr 3.14TCr 48Cr 323.61Cr 125.22Cr 1.55TCr 125.09Cr 122.36Cr 5.39TCr
Net income -1.4Cr -1.22Cr -1.13Cr -1.06Cr -1.98Cr -131.63Cr -2.02Cr -14Cr -5.24Cr -65Cr -5.24Cr -5.13Cr -225.58Cr 4.65Cr 4.08Cr 3.76Cr 3.52Cr 6.6Cr 439.11Cr 6.74Cr 45Cr 17Cr 217.02Cr 17Cr 17Cr 752.52Cr
Net Debt -2.1Cr -1.84Cr -1.69Cr -1.59Cr -2.98Cr -197.81Cr -3.04Cr -20Cr -7.88Cr -98Cr -7.87Cr -7.7Cr -338.99Cr -17Cr -15Cr -14Cr -13Cr -24Cr -1.59TCr -24Cr -164.17Cr -64Cr -787.91Cr -63Cr -62Cr -2.73TCr
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26/26/26 $1.320 -3.65% 1,16,14,682
25/26/25 $1.370 -1.08% 95,46,037
24/26/24 $1.385 +2.59% 1,92,34,596
23/26/23 $1.350 +0.75% 1,31,03,262
22/26/22 $1.340 +6.35% 1,87,13,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.370USD
Average target price
3.400USD
Spread / Average Target
+148.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock